<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741623</url>
  </required_header>
  <id_info>
    <org_study_id>Ipca/ARL-12/147</org_study_id>
    <nct_id>NCT01741623</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition</brief_title>
  <official_title>A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IPCA Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IPCA Laboratories Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single&#xD;
      dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence&#xD;
      between Test Product and the corresponding Reference Product under fasting condition in&#xD;
      normal, healthy, adult human subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this pivotal study was to assess the bioequivalence between Test Product:&#xD;
      Bisoprolol Fumarate Tablet 10 mg of Ipca Laboratories Limited, India and the corresponding&#xD;
      Reference Product: Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals&#xD;
      Inc., USA under fasting condition in normal, healthy, adult, human subjects in a randomized&#xD;
      crossover study.&#xD;
&#xD;
      The study was conducted with 24 healthy adult subjects. In each study period, a single 10 mg&#xD;
      dose of either test or reference was administered to the subjects as per the randomization&#xD;
      schedule in each study period with about 240 mL of water at ambient temperature in sitting&#xD;
      position.&#xD;
&#xD;
      The duration of the clinical phase was approximately 15 days including washout period of at&#xD;
      least 10 days between administrations of study drug in each study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>3 months</time_frame>
    <description>pre-dose, 00.50, 01.00, 01.50, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 07.00, 08.00, 10.00, 12.00, 16.00, 20.00, 24.00, 48.00 and 72.00 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-dose and at 00.50, 01.00, 01.50, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 07.00, 08.00, 10.00, 12.00, 16.00, 20.00, 24.00, 48.00 and 72.00 hours post-dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Bisoprolol Fumarate Tablet 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zebeta®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol Fumarate Tablet 10 mg</intervention_name>
    <description>10 mg tablet once a day</description>
    <arm_group_label>Bisoprolol Fumarate Tablet 10 mg</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>10 mg tablet once a day</description>
    <arm_group_label>Zebeta®</arm_group_label>
    <other_name>Zebeta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and Non-pregnant female human subjects, age in the range of 18 - 45 years (both&#xD;
             inclusive).&#xD;
&#xD;
          2. Body weight within ± 15% of ideal weight as related to height and body frame according&#xD;
             to Life Insurance Corporation (LIC) Chart.&#xD;
&#xD;
          3. Subjects with normal findings as determined by baseline history, physical examination&#xD;
             and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).&#xD;
&#xD;
          4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry,&#xD;
             serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray&#xD;
             (chest X-ray if required).&#xD;
&#xD;
          5. Willingness to follow the protocol requirements as evidenced by written informed&#xD;
             consent.&#xD;
&#xD;
          6. Subject willing to give written informed consent.&#xD;
&#xD;
          7. Confirming and agreeing to, not using any prescription and over the counter&#xD;
             medications including vitamins and minerals for 14 days prior to study and during the&#xD;
             course of the study.&#xD;
&#xD;
          8. No history of drug abuse in the past one year.&#xD;
&#xD;
          9. Non-smokers and non-alcoholics.&#xD;
&#xD;
         10. For female subject&#xD;
&#xD;
               -  was child bearing potential practicing acceptable method of birth control for the&#xD;
                  duration of the study as judged by Investigator such as Condom, Foams, Jellies,&#xD;
                  Diaphragm, Intrauterine device and Abstinence.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  was surgically sterile (bilateral tubal ligation, bilateral oophorectomy or&#xD;
             hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of hypersensitivity to Bisoprolol Fumarate, or related drugs.&#xD;
&#xD;
          2. Requiring medication for any ailment having enzyme-modifying activity in the previous&#xD;
             28 days, prior to dosing day.&#xD;
&#xD;
          3. Any medical or surgical conditions, which might significantly interfere with the&#xD;
             functioning of gastrointestinal tract, blood-forming organs etc.&#xD;
&#xD;
          4. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
             metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric&#xD;
             diseases and bleeding tendency.&#xD;
&#xD;
          5. Participation in a clinical drug study or bioequivalence study within 90 days prior to&#xD;
             present study.&#xD;
&#xD;
          6. History of malignancy or other serious diseases.&#xD;
&#xD;
          7. Refusal to abstain from food for at least 10.00 hours prior to study drug&#xD;
             administration and for at least 04.00 hours post-dose, in each study period.&#xD;
&#xD;
          8. Any contraindication to blood sampling or difficulty in accessibility of veins.&#xD;
&#xD;
          9. Refusal to abstain from fluid for at least 01.00 hour prior to study drug&#xD;
             administration and for at least 01.00 additional hour post-dose, in each study period&#xD;
             except about 240 mL of water given during administration of study drug.&#xD;
&#xD;
         10. Refusal to avoid the use of xanthine-containing food or beverages (chocolates, tea,&#xD;
             coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for&#xD;
             48.00 hours prior to dosing until the last blood sample collection of last study&#xD;
             period.&#xD;
&#xD;
         11. Blood donation within 90 days prior to the commencement of the study.&#xD;
&#xD;
         12. Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.&#xD;
&#xD;
         13. Found positive in breath alcohol test done before check-in for each study period.&#xD;
&#xD;
         14. Found positive in urine test for drugs of abuse done before check-in for each study&#xD;
             period.&#xD;
&#xD;
         15. Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing&#xD;
             until the last blood sample collection of last study period.&#xD;
&#xD;
         16. History of problem in swallowing Tablet(s).&#xD;
&#xD;
         17. Female subject, demonstrating positive urine pregnancy test at the time of screening.&#xD;
&#xD;
         18. Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic&#xD;
             Gonadotropin) test before check-in for each study period.&#xD;
&#xD;
         19. Female subject, currently breast feeding or lactating.&#xD;
&#xD;
         20. Female subjects not willing to use acceptable method of contraception from the date of&#xD;
             screening until the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Rupesh Vala, M.B.B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Lab (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Lab (I) Pvt. Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 1, 2012</study_first_submitted>
  <study_first_submitted_qc>December 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 1, 2012</last_update_submitted>
  <last_update_submitted_qc>December 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

